ASCO 2025 preview – KRAS challengers assemble
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
Qilu nabs a new B7-H3 contender
Minghui’s MHB088C will soon start phase 3 in China.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
AACR 2025 – Merck's head and neck headscratcher
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
AUA 2025 – J&J scores in a new bladder cancer use
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.